The possibility of insertional mutagenesis in retroviral gene therapy can be reduced by using a vector lacking the enhancer sequence present in the U3 of the long-terminal repeats. However, such vectors suffer from many pitfalls. We attempted to improve a murine leukemia virus-based retroviral vector containing the enhancer-free U3, first by making it easier to construct a producer line and then by introducing the cellular RPL10 promoter as an internal promoter. The reverse orientation of the expression cassette of the transgene was found to give higher transducing titer and higher-level gene expression. The deletion analysis revealed that the 54-bp-long sequence of U3 (34 and 20 bp present at 5¢ and 3¢ extreme ends, respectively) was sufficient for the functions of retroviral vectors. The data from the in vitro cell culture assay indicated that the final construct, ROK, containing all these features, had little cis-activation activity, even if it was placed right upstream from the RNA start site of the neighboring gene. Our data suggested that the newly developed vector might provide increased safety, while still producing high viral titer from a stable producer line and high-level gene expression in various target cells including human CD34 + stem cells.
INTRODUCTION
Murine leukemia virus (MLV)-based retroviral vectors are one of the most frequently used gene delivery vehicles in marking studies, as well as in clinical investigations testing their safety and efficacy. 1 It is well known that the retrovirus can generate the insertional mutation by virtue of its biology, namely, the integration of its genetic information into the host chromosome, which can lead to the disruption, activation or transduction of cellular genes (reviewed in Uren et al. 2 ) In the case of replication-defective retroviral vectors used in the gene therapy setting, however, the risk of insertional mutagenesis had initially been thought to be very low, as the frequency of retroviral insertion promoting a malignant phenotype was estimated to be about 10 À7 per insertion and additional mutations were needed to develop tumors. 3 However, the X-linked severe combined immunodeficiency trial done by Marina Cavazzana-Calvo's group showed that insertional mutagenesis could indeed occur. It was reported that the delivery of the common g-chain gene by a retroviral vector could provide clinical benefits to these patients, 4 but subsequently that four subjects who had received transduced CD34 + cells developed lymphoproliferative disorders. 5, 6 The molecular analysis revealed that the carcinogenesis might have resulted at least in part from the cis-activation of the neighboring genes, LMO2, BMI1 and CCND2, around which the vector genome had integrated. 5, 6 Because other similar malignancies and clonal dominance were found in other gene therapy trials, 7, 8 it is now clear that the issue of the possibility of insertional mutagenesis needs to be addressed, in order for this type of vector to become a viable form of gene delivery vehicle in the human gene therapy setting.
There are several ways of addressing these issues. For example, the vector may be rendered to integrate into the specific site. Many attempts have been made, but it remains to be seen whether their results can be useful for the actual clinical application. 9, 10 Another possibility is to use terminally differentiated cells as targets. 11 This strategy may be chosen for diseases in which transgene expression can generate therapeutic effects, even if it is expressed during a limited period of time in specific cell types. Other investigators have considered expressing the suicidal gene, together with the therapeutic gene. 12 Under this scenario, cells containing the transgene can be eliminated by the respective drug, when transduced cells behave abnormally or when their mission is accomplished.
No matter which strategy is used to minimize the carcinogenesis, the current form of retroviral vector is still not in its optimum form from the viewpoint of insertional mutagenesis, and needs to be improved. In this study, we attempted to upgrade the safety features of MLV-based retroviral vectors by engineering the nucleotide sequences with following considerations.
First, in the context of gene therapy, the main reason for retroviral insertional mutagenesis appears to be the long terminal repeatmediated enhanced expression of the gene present near the integrated retroviral vector as originally shown by Li et al. 13 The analysis of leukemia cases found in the X-linked severe combined immunodeficiency gene therapy trials also strongly points out that the same is true in humans. [5] [6] [7] This suggests that after the retroviral vector integrates into the host chromosome, both the 5¢ and 3¢ LTRs have to be transcriptionally defective. Yu et al. 14 developed the method of constructing such a retroviral vector, namely a self-inactivating (SIN) vector, which can be used as the basis for making both 5¢ and 3¢ U3 transcriptionally inactive.
Second, the presence of non-functional LTR means that the new control element has to be introduced into the retroviral genome as an internal promoter. The HCMV (human cytomegalovirus) immediate early promoter and the spleen focus forming virus LTR have been frequently used, 15, 16 but these are also viral promoters known to contain the enhancer element. 17, 18 Furthermore, the viral promoter, like the HCMV immediate early promoter, has often been found to be silenced for gene expression with the passage of time. 19 Ideally, the internal promoter may be chosen from cellular promoters, which are not capable of activating neighboring genes, for example, by having no enhancer sequences.
Third, the introduction of an internal promoter to the middle of the vector genome has often resulted in decrease in transducing titer and the level of gene expression. 16, 20 Furthermore, the performance of the internal promoter has been found to be influenced by the nature of the transgene. 21 Therefore, an optimum internal promoter has to be determined in an empirical manner.
Based on such logic, we set out to perform a series of experiments, which finally led us to the development of a retroviral vector, called ROK, which contains only 54 bp of U3. Our newly developed vector was engineered to express the gene of interest from the internal cellular promoter RPL10 in the reverse orientation relative to the 5¢LTR. It was found that the ROK vector generated high titer in a producer line, as well as gave a high level of gene expression in transduced cells. In an in vitro cell culture assay, the vector had little effect on the neighboring LMO2 promoter, even if it was placed immediately upstream from the RNA start site of that gene. Our results indicated that vector ROK might provide increased safety, while containing at least the same degree of vector functions.
RESULTS

Construction of prototype vector ID
The starting molecule was the retroviral vector called MT. 22 MT is a minimum-size MLV-based vector that does not contain any viral coding sequences, and has previously been shown to produce no replication competent retrovirus. 23 In the context of plasmid DNA, ID was derived from MT by deleting 310 bp from the 447-bp-long U3 present in the 3¢ LTR and by inserting a multi-cloning site as shown in Figure 1 . To readily make a stable producer line, two SmiI restriction sites were created in the plasmid backbone. These sites can be used to linearize the entire plasmid before the electroporation, which allows the whole retroviral vector DNA to integrate into the chromosome without disruption of the nucleotide sequences necessary for vector functions. 24, 25 The neomycin-resistant gene cassette was also introduced, which will be used to select cells transfected with vector DNA. The final structure of plasmid containing the retroviral vector DNA was named ID (Figure 1 ).
Screening for an optimum internal promoter A variety of human promoters were analyzed using the ENCODE (encyclopedia of DNA element) project. 26 The initial criterion was the level of gene expression. Eleven cellular promoters that are thought to drive a high level of transcription were chosen for the comparison. The HCMV immediate early or the human b-actin promoters were used as a control, as they have been shown to drive a high level of gene expression in many different settings. For the convenience of screening, the 5¢ end of promoters was taken from approximately 350 bp upstream from the RNA initiation site (+1), with the 3¢ end being right down to the translation start codon (ATG). The 5¢ untranslated region was added because in many genes it positively influences the level of gene expression. The cloned promoter fragments were inserted into retroviral vector ID to drive the expression of enhanced green fluorescent protein (eGFP).
Retroviral vectors containing various cellular promoters were compared by using a 3-plasmid transfection method. 27 Plasmid DNAs having the retroviral vector sequence were transfected to 293T cells, and 2 days later, cell-free viral supernatants were taken to transduce two human cell lines: HT1080, a human fibrosarcoma cell line, and K562, a human erythroleukemic line. Two days later, transduced cells were analyzed by fluorescence-activated cell sorter (FACS). There was no difference in the percentage of transgene-positive cells at 2, 4 and 9 days after transduction (data not shown). In this assay, the mean fluorescence intensity represents the level of gene expression, whereas the percentage of eGFP-positive cells indicates transducing titer. In Table 1 , the data from this assay were arranged, according to the percentage of eGFP-positive cells, with the value from the HCMV promoter-containing retroviral vector being 100. A similar level of transduction efficiency was observed in both human cell lines, whereas the mean fluorescence intensity was generally lower in HT1080 than that in K562. Two retroviral vectors, each containing LENG8 or RPL10 promoters, showed the highest transduction efficiency, in both cell lines, although their level of gene expression was lower than that from the HCMV promoter. LENG8 and RPL10 are known to encode human leukocyte receptor cluster member 8 and human ribosomal protein L10, respectively. Although the EF1a promoter that had been frequently used as an internal promoter in SIN-based retroviral vectors showed a high level of gene expression, the presence of this promoter sequence dramatically decreased the transducing titer of our retroviral vector (Table 1) . 28, 29 It is known that the transducing titer and the level of gene expression from a retroviral vector can be highly influenced by the nature of complementary (c)DNA sequence inserted into the vector (for example, see Yu et al. 23 ). To make sure that the above observation is not an artifact resulting from the use of a particular sequence, another reporter gene was used. The human gp91 phox cDNA sequence codes for one of six proteins constituting the NADPH oxidase system present on the cell membrane. Six promoters showing higher transduction efficiency in the above experiment were chosen for further comparative analysis. In this assay, a retroviral vector containing the MLV LTR, MT-gp91, was used as a positive control, as the HCMV immediate early promoter always gave low transducing titer and lowlevel gene expression when the gp91 phox sequence was present in the vector. As summarized in Table 2 , two retroviral vectors, each containing the RPL10 and SNX3 (known to encode human sorting nexin 3) promoters, gave the highest percentage of transduced cells, and also produced a reasonable level of gene expression, as measured by the mean fluorescence intensity in both human cell lines: K562 cells stably expressing p47 phox and p67 phox , and X-CGD PLB-985 cell line deficient in gp91 phox . 30 However, it has to be noted that the level of both parameters, intensity and percentage, was still lower than that from MT-gp91 using the wild-type MLV LTR. As shown later, it is due in part to the fact that the human promoters used in this analysis are not a full-length control element, while MT-gp91 uses the original wild-type LTR. In summary, the promoter from RPL10 performed well in both eGFP and gp91 phox sequences, relative to other cellular promoters, and was chosen for further studies.
Optimization of the RPL10 promoter
The above studies indicated that the RPL10 promoter might be an ideal cellular sequence in the context of the retroviral vector. However, the RPL10 promoter used in the above experiment contains only 350 bp upstream from the RNA start site, so the optimum length of the promoter was searched. For convenience of testing, various promoter fragments were cloned into a reporter plasmid designed to express eGFP by the promoter sequence to be inserted. These expression vectors were transfected to 293T cells, followed by FACS analysis. Figure 2a showed that the mean fluorescence intensity increased as the length of promoter became longer, and the 1-kb promoter fragment gave the highest level of gene expression.
To confirm this result in the context of the retroviral vector, the 1-kb and original 350-bp promoter fragments of RPL10 were cloned to retroviral vector ID to drive the expression of gp91 phox , resulting in RKD-gp91 and RD-gp91, respectively. Plasmid DNAs having the retroviral vector sequence were transfected to 293T, and cell-free viral supernatants were taken to transduce K562 cells. Two days later, FACS analysis was performed, using anti-gp91 phox antibody. The mean fluorescence intensity of RKD-gp91 was about 50% higher than that of RD-gp91, while the two vectors showed similar transduction efficiency (Figure 2b ). Based on this observation, the 1-kb promoter fragment of RPL10 was chosen as the final internal promoter of ID vector. Abbreviations: GAPDH, glyceraldehyde-3-phosphate dehydrogenase promoter; HCMV, human cytomegalovirus immediate early promoter; ITGB4P, integrin beta 4 binding protein promoter; LENG8, leukocyte receptor cluster member 8 promoter; RPL10, ribosomal protein L10 promoter; SNX3, sorting nexin 3 promoter. a Transducing titer of the reference vector, MT-gp91, was 1.8Â10 7 and 1.4Â10 6 TU ml À1 when measured in K562 p47phox+ p67phox+ and X-CGD PLB-985, respectively. The average vector copy numbers of the reference vector, MT-gp91, were 4.5 and 5.2 in K562 p47phox+ p67phox+ and X-CGD PLB-985 cells, respectively. Four independent experiments were performed for both cell lines.
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Effect of orientation of expression cassette It was reported that the orientation of the expression cassette (consisting of internal promoter and cDNA sequence) could affect the performance of the retroviral vector. 31, 32 Therefore, the two vectors were compared by making a stable producer line, RKD-gp91 containing the expression cassette in the 'forward' orientation and ROKD-gp91 in the 'reverse' orientation ( Figure 3 ). Vector plasmid DNAs were linearized and transfected to PG13 cells by electroporation, followed by G418 selection. This method was employed because with retroviral vectors containing defective U3, a traditional 'pingpong' method 33 could not be used, and DNA transfection is the only way to make a producer line. The same volume of culture supernatants from drug-resistant populations was used to transduce K562 cells. Two days later, FACS analysis was performed, using anti-gp91 phox antibody. When measured by the percentage of gp91 phox -positive cells, ROKD-gp91 produced about four times higher transducing titer than RKD-gp91 (Figure 3) , while also giving a higher level of gene expression as determined by the mean fluorescence intensity, not only in this experiment, but also when the same transducing titer was used (data not shown). To test whether this result was influenced by the nature of cDNA sequence, the eGFP sequence was also used as a reporter gene. Consistent with the gp91 phox data, both transducing titer and the level of eGFP expression from the reverse orientation vector, ROKD-eGFP, were higher ( Figure 3 ). These results indicated that the reverse position of the expression cassette significantly increased transducing titer in stable producer lines, as well as the level of gene expression in transduced cells.
Identification of minimum size U3
The U3 region used in the above studies contains a 310-bp deletion lacking the enhancer sequences, while still harboring promoter sequences such as CAAT and TATA boxes. These remaining promoter elements may contribute to the read-through transcription, resulting in cis-activation of the neighboring gene expression. In the case of spleen focus forming virus and murine stem cell virus, it has previously been shown that CAAT and TATA sequences could be deleted without having negative impacts on the vector function. 16, 34 According to our knowledge, however, the minimum size of U3 has not been clearly determined for moloney murine leukemia virus. To test the possibility of eliminating any residual transcriptional activity, the U3 region was further deleted, resulting in another two constructs, ROKT-gp91 containing TATA and Figure 2 Determination of the optimum length of RPL10 promoter. (a) Various lengths of the RPL10 promoter were cloned into a reporter plasmid that is designed to express eGFP by the promoter sequence to be inserted. Expression vectors were transfected to 293T, followed by FACS analysis. Mean fluorescence intensity from À50 bp RPL10 promoter was set to 1, and those of others were normalized to it. The results are shown as mean ± s.d. of three independent experiments. (b) Two retroviral vectors (RD-gp91, containing À350 bp RPL10 promoter, and RKD-gp91, containing À1000 bp RPL10 promoter) were transfected to 293T using a three-plasmid transfection method. 27 Two days later, the same volume of viral supernatants was taken to transduce K562, followed by FACS analysis using anti-gp91 phox antibody. The results are shown as mean ± s.d. of three independent experiments.
Development of murine leukemia virus (MLV)-based retroviral vectors J Jang et al ROK-gp91 having only 20 bp upstream from the +1 position ( Figure 4 ). Three vectors were linearized and electroporated to PG13 cells, followed by G418 selection. Drug-resistant populations were obtained, and the same volume of culture supernatants was taken to transduce K562 cells, followed by FACS analysis. As shown in Figure 4 , the percentage of gp91 phox -positive cells of ROK-gp91 (31.67%) was higher than that of ROKD-gp91 (27.97%) and ROKT-gp91 (27.09%). Furthermore, the mean fluorescence intensity of ROK-gp91 was higher than that of ROKD-gp91 and ROKT-gp91. These data indicated that almost all nucleotide sequences could be deleted from U3, without significant effects on transducing titer and the level of gene expression, in the context of this particular type of retroviral vector.
Comparison of the newly developed vector with other well-known retroviral vectors MFG 4,35,36 and MT 22, 23, 37 are well-characterized retroviral vectors and have been used in actual clinical trials. Therefore, the performance of ROK-gp91 was compared with these vectors. MFG and MT are retroviral vectors containing the wild-type LTRs and their producer lines were prepared by the 'ping-pong' method. 33 293T cells were transfected with the respective vector DNA and cell-free viral supernatants were taken to transduce the PG13 packaging cell line. Transduced cells were seeded onto 96-well plates by using a limiting dilution method. In the case of ROK, PG13 cells were transfected with the linearized vector DNA, followed by G418 selection. The drugresistant population was obtained and plated onto 96-well plates by Figure 3 Effect of orientation of the expression cassette on transducing titer and the level of gene expression. Retroviral vectors containing the expression cassette in the forward orientation (RKD) and in the reverse orientation (ROKD) were linearized, and transfected to PG13 cells by electroporation, followed by G418 selection. The same volume of culture supernatants from drug-resistant populations was used to transduce K562. In the case of gp91 phox , transduction was performed three times, while one round of transduction was sufficient for eGFP-expressing retroviral vectors. Two days later, samples were analyzed by FACS. Representative data from three independent experiments are shown. Nucleotide positions of RKD-gp91 and ROKD-gp91 are provided, as those of RKD-GFP and ROKD-GFP are shown in parentheses.
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J Jang et al limiting dilution. We isolated 27, 51 and 49 subclones for MFG, MT and ROK, respectively. On the 24-well plate, all three vectors showed a similar range of viral production, from 10 2 to 10 5 TU ml À1 . Two or three subclones producing the highest viral titer were chosen and further expanded. On the 10-cm plate, the highest transducing titer obtained for MFG-gp91, MT-gp91 and ROK-gp91 vector was 3.3Â10 6 , 9Â10 5 and 4.7Â10 6 TU ml À1 , respectively, as measured by FACS using K562 cells. 38 When the same volume of viral supernatant was taken from each producer line and used to transduce K562 cells, the percentage of gp91 phox -positive cells showed a pattern expected from the amount of viral vectors produced from respective producer lines, with ROK-gp91 generating the highest percentage of transduced cells (Figure 5a ). When the same titer of retroviral vectors (MOI¼0.4) was used, the mean fluorescence intensity of ROK-gp91 was about 50% lower than that of MT-gp91, but 1.5-fold higher than that of MFG-gp91 (Figure 5b) . To investigate the performance of ROK-gp91 in other cells, we transduced X-CGD PLB-985 cells and human CD34 + cells with the same titer of retroviral vectors, as measured by using K562 cells. In X-CGD PLB-985 cells, the mean fluorescence intensity of ROK-gp91 was similar to that of MFG-gp91, but lower than that of MT-gp91. When human CD34 + cells were used as target cells, ROK-gp91 showed a reasonable level of gene expression, although the exact comparison of gene expression between retroviral vectors was difficult due to different transduction efficiency (Figure 5b ). These data suggested that the newly developed retroviral vector, containing minimum-size U3 sequences and the 1-kb RPL10 promoter in a reverse orientation, might perform better than or comparable to retroviral vectors using the original wild-type LTR.
Testing the possibility of cis-activation of the neighboring gene using an in vitro assay system We previously reported the development of the in vitro cell culture assay in which the effect of retroviral integration on the neighboring gene can be evaluated. 25 A newly developed vector, ROK-gp91, was tested using this assay. In this system, the retroviral vector was placed upstream from the RNA start site of the LMO2 gene whose coding sequence was replaced with the CAT sequence ( Figure 6 ). Here, the 5-kb-long promoter and 0.43 kb untranslated region from the LMO2 gene drive the CAT expression. pMT or pROK was engineered to be placed 5 kb upstream from or immediately next to the +1 site of LMO2. Plasmid DNAs containing these retroviral vector sequences were linearized and transfected to K562 cells by electroporation, followed by G418 selection. After drug-resistant populations were obtained, the level of CAT activity was determined. The level of CAT expression from pMT-gp91 was higher by 3.5-or 158-fold than that from pNRT containing no retroviral sequence, depending on the position of the vector sequence relative to the RNA start site. In contrast, a newly developed vector did not have any significant effect on the LMO2 promoter, regardless Figure 4 Determination of minimum length of U3. Three retroviral vectors containing CAAT and TATA boxes (ROKD), TATA box only (ROKT), or no promoter elements (ROK) in U3 were linearized and transfected to PG13 cells by electroporation, followed by G418 selection. The same volume of culture supernatants from drug-resistant populations was used to transduce K562. Two days later, FACS analysis was performed using anti-gp91 phox antibody. Representative results from two independent experiments are shown.
J Jang et al of its position ( Figure 6 ). To be certain, the retroviral vector genome was also placed in a reverse orientation relative to the CAT sequence. The level of CAT activity from this vector, pROK-rev, was similar to that from pNRT.
We also measured the level of CAT mRNA by real-time quantitative reverse transcriptase-PCR. The level of CAT mRNA from pMT (5 kb) was 2.2-fold higher than that from pNRT, whereas pROK (5 kb) did not show the increased expression ( Figure 6 ). When the retroviral vectors were placed immediately next to the +1 site of LMO2, the level of CAT mRNA from pMT was increased 66 times higher than that from pNRT containing no vector sequence. In ROK vector, however, the level of CAT mRNA was not changed significantly, regardless of the orientation of the integrated vector genome (Figure 6 ). These results confirmed that retroviral vectors containing the wild-type LTR could highly activate the neighboring cellular promoter, whereas the possibility of such cis-activation might be very low in our newly developed vector, ROK-gp91.
DISCUSSION
One of the key factors limiting the success of retroviral gene therapy is the issue of possible insertional mutagenesis inherent to all retroviruses. In this study, we attempted to improve MLV-based retroviral vectors in various ways. The starting point was to make a particular SIN type of retroviral vector more user friendly. When the 3¢ LTR is rendered to have the defective U3, a producer line cannot be conveniently made, for example by using a conventional 'ping-pong' method. 33 Our ID vector plasmid overcomes such a problem by inserting appropriate restriction SmiI sites and the selectable marker in the plasmid backbone, thus allowing us to readily construct a producer line. The ID vector was further engineered to contain the cellular RPL10 promoter, the expression cassette in a reverse orientation and only 54 bp of the U3. The final construct was demonstrated to produce transducing titer and a level of gene expression similar to previous retroviral vectors harboring the wild-type LTRs. The data from an in vitro cell culture assay suggested that the vector had little Figure 5 Comparison between the newly developed retroviral vector (ROK) and other well-characterized vectors containing two wild-type LTRs, MFG and MT. (a) The same volume of viral supernatants from producer lines, originated from a single clone, with highest transducing titer was taken to transduce K562. Two days later, FACS analysis was performed using anti-gp91 phox antibody. Representative data from three independent experiments are shown. (b) The same titer of retroviral vectors, as measured by using K562 cells, was taken to transduce K562 (moi¼0.4), X-CGD PLB-985 (moi¼1) and CD34 + cells (moi¼3). In the case of X-CGD PLB-985 and CD34 + cells, three rounds of transduction were performed. Two days later, samples were analyzed by FACS using anti-gp91 phox antibody. Representative data from three independent experiments are shown.
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One bottleneck associated with the use of the internal promoter in the SIN vector has been the decrease in transducing titer and the level of gene expression, resulting from various causes. 16, 20 It is known that the transducing titer of a SIN vector can be influenced by the internal promoter sequence inserted into the vector, 16 and our approach was to screen a variety of cellular promoters to find an optimum one. Through extensive comparative studies, the RPL10 promoter was finally chosen. The retroviral vector containing the RPL10 promoter produced a reasonable level of gene expression and viral titer. The human RPL10 gene is located on chromosome Xq28 and encodes a ribosomal protein that is a component of the 60S subunit. It is known to be a housekeeping gene with increased expression in the liver, spleen, testis and adrenal gland. 39 The data from our cell culture-based assay suggested that even if our vector is inserted right next to the RNA start site of the neighboring gene, the possibility of cis-activation of that gene by the vector sequence would be very low. It is probably due to the fact that our final vector contains no enhancer sequence, and/or that the transcription termination signals present in the R region of both LTRs might act as a barricade, which prevent or protect the inside sequences from influencing or being influenced by the expression of the neighboring gene. 25 To prove that the newly developed vector system does not induce cancer in vivo, we are currently performing extensive experiments on mice, as recommended by the US Food and Drug Administration (http://www.fda.gov/ohrms/dockets/ac/06/ briefing/2006-4205B2_3.pdf).
One technical problem with using a SIN-based retroviral vector is the difficulty in making a stable producer line. We overcame this hurdle by introducing the convenient restriction sites and the selectable marker to the plasmid backbone, which could be used to construct a stable producer line by electroporation-mediated transfection. We were able to obtain a stable PG13 line that could produce 8Â10 5 TU ml À1 in HT1080. When the codon usage of gp91 phox was optimized, the titer and the level of gene expression could be further improved by twofold (data not shown). Loew et al. 40 recently reported the construction of PG13-based stable producer lines, which produced 1-4Â10 5 TU ml À1 from an SIN type g-retroviral vector containing codon-optimized gp91 phox , using the cassette exchange technology. Although it is difficult to directly compare the data from these two different works, the strategy used in our ROK system might be considered one useful way of constructing a stable producer line from a SIN-based vector.
Despite the recent drawbacks of retroviral vectors, primarily due to leukemia cases, MLV-based vectors still offer distinct advantages in selective cases, as compared with other retroviral vectors. Biologically, MLV is one of the most well-characterized retroviruses. It is simpler and safer to engineer and produce in a large scale, for example, relative to HIV-based retroviral vectors. The disadvantage that it cannot deliver the gene to non-dividing cells may be overcome by the recent progresses in the area of in vitro cell culturing technologies. MLVbased vectors may still be the most practical form of gene delivery vehicle for certain diseases, as long as the possibility of insertional mutagenesis is rendered to be nil or very low. Our data strongly suggest that our vector system can not only produce reasonable levels of transducing titer and gene expression, which are vital for the efficacy of the vector, but may also have very low possibility of inducing carcinogenesis resulting from cis-activation by the vector sequence.
MATERIALS AND METHODS
The materials and methods for the promoter cloning, deletion analysis of RPL10 promoter, construction of retroviral vectors, staining of gp91 phox -positive cells and determination of vector copy number are described in Supplementary Materials and Methods.
Cell culture
293T (CRL-11268), HT1080 (CCL-121) and PG13 (CRL-10686) were purchased from the American Type Culture Collection. These cells were Figure 6 Effect of integrated retroviral vector sequences on the expression of the neighboring gene. The structure of the retroviral genome and the relative position of the LMO2 control region are shown. The defective U3 is indicated as the shaded box. Two retroviral vector sequences were placed 5 kb upstream from or immediately next to the RNA start site of LMO2, respectively. All the plasmids were linearized and transfected to K562 by electroporation. Once the stably transfected cell populations were obtained after G418 selection, the levels of CAT activity and mRNA were analyzed by CAT assay and qRT-PCR, respectively, and normalized to the vector copy number. The results are shown as mean ± s.d. of four independent experiments.
Development of murine leukemia virus (MLV)-based retroviral vectors J Jang et al maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS). K562 (CCL-243) was purchased from the American Type Culture Collection and cultured in RPMI1640 supplemented with 10% FBS. K562 stably expressing p47 phox and p67 phox was constructed by using MIN 23 and MIH retroviral vectors containing respective cDNA sequences. (MIH is identical to MIN except that the former contains a hygromycinresistance gene instead of the Neo sequence.) X-CGD PLB-985 was kindly provided by Dr MC Dinauer.
Retroviral vector production and transduction
Retroviral vector plasmids were transfected into 293T cells with pVM-GP and amphotropic env expressing pVM-AE or GaLV env expressing pVM-GeR using FuGene6 (Roche, Mannheim, Germany) according to the manufacturer's instructions. 37, 41 Supernatants were collected 48 h after transfection, filtered through a 0.45-mm filter and used for the transduction of target cells. The detailed method of constructing PG13 stable producer lines for retroviral vectors containing wild-type LTRs was previously described. 42 Briefly, MFGgp91 and MT-gp91 retroviral vectors were prepared from 293T cells by a threeplasmid transfection method 27 and used to transduce PG13 packaging cells. After transduction, PG13 cells were seeded onto 96-well plates at a concentration of 0.3 cells per well. About 2 weeks after incubation, clones were transferred to 24-well plates, and when cells were grown to about 80% confluency, viral supernatants were taken to determine the titer by a one-step quantitative reverse transcriptase PCR reaction, using the forward primer MIN 5¢ (5¢-TTCTGGTAGGAGACGAGAACCTAAA-3¢), the reverse primer MIN 3¢ (5¢-ACAGAGACAACACAGAACGATGCT-3¢) and the probe (VIC-5¢-CA GTTCCCGCCTCCGTCTGAATTTTT-3¢-TAMRA). Of these clones, two or three clones that showed the highest titer were chosen and further expanded. To make PG13 stable producer lines from SIN type retroviral vectors, 7.5Â10 5 PG13 packaging cells were added in a 0.5-ml volume of serum-free Dulbecco's modified Eagle's medium to the 0.4-cm cuvette (Bio-Rad Laboratories, Hercules, CA, USA) and incubated with linearized retroviral plasmid (1 mg) for 5 min preceding electroporation. Electroporations (200 V, 20 ms) were conducted using Gene Pulser Xcell (Bio-Rad Laboratories). Following electroporation, suspensions were plated in Dulbecco's modified Eagle's medium with 10% FBS and grown in the presence of G418 (1 mg ml À1 ). The single clone showing the highest titer was chosen by using a limiting dilution method, as described above. To prepare viruses, 5Â10 6 cells of PG13 packaging cell line were plated on 100-mm dishes in Dulbecco's modified Eagle's medium with 10% FBS. After 2 or 3 days, supernatants were harvested and filtered through a 0.45-mm filter.
For transduction, HT1080 cells were seeded at 1Â10 5 in six-well plates on the previous day. Viral supernatants were added in the presence of polybrene (8 mg ml À1 ). Two days after transduction, flow cytometry was performed on a FACS (BD, Los Angeles, CA, USA) with the aid of CellQuest software. K562, K562 p47phox+/p67phox+ or X-CGD PLB-985 cells were seeded at 5Â10 5 cells in six-well plates. Viral supernatants were added in the presence of polybrene (8 mg ml À1 ) and plates were centrifuged at 2800 r.p.m. for 2 h. After centrifugation, cells were incubated at 37 1C for 2 h, then washed and re-fed with a fresh RPMI1640 medium supplemented with 10% FBS. For X-CGD PLB-985, two extra rounds of transductions were performed, and 2 days later, cells were analyzed by FACS. In the case of human CD34 + cells, cells were purchased from POIETICS (Gaithersburg, MD, USA). Before retroviral transduction, CD34 + cells were prestimulated for 2 days in stem cell growth medium (CellGenix, Freiburg, Germany) containing 300 ng ml À1 human stem cell factor, 300 ng ml À1 hFlt-3 ligand, 100 ng ml À1 hTPO and 20 ng ml À1 hIL-3 (R&D Systems, Minneapolis, MN, USA). The cells were transduced three times with the viral supernatant on RetroNectin (Takara, Otsu, Japan)-coated plates over a period of 2 days. Finally, cells were incubated at 37 1C, 5% CO 2 for 48 h, followed by FACS analysis.
In vitro cell culture assay for measuring the activation of a neighboring gene
The detailed procedure for this assay was previously described. 25 Briefly, the EcoRI (Klenow-blunted)-NdeI fragment of MT-gp91 was cloned to the SalI (Klenow-blunted)-NdeI site of pMT, yielding pMT-gp91. To construct the proviral form of ROK-gp91, the deleted form of 5¢LTR was amplified from plasmid ROK-gp91 using primers 5¢dLTR F (5¢-GCTAGCCCCACAACCCCTC ACTCG-3¢) and 5¢dLTR R (5¢-ACGCGTATTTTCAGACAAATACAGAAACAC AGTCAG-3¢). The amplified fragment was initially cloned into Gem T easy (Promega, Madison, WI, USA), resulting in Gem T easy-5¢dLTR. The NheIMluI fragment was cloned into the NheI-MluI site of ID. The multi-cloning site, RK promoter, gp91 phox cDNA and RGpA were introduced into this plasmid as described in Supplementary Materials and Methods. The NdeI-SalI fragment of the proviral form of ROK-gp91 was introduced to the NdeI-SalI site of pMT, yielding pROK-gp91. To construct pROK-gp91-rev, the NdeI-SalI fragment (Klenow-blunted) of the proviral form of ROK-gp91 was inserted to the NdeI-SalI site (Klenow-blunted) of pMT. In all, 9 mg of the respective plasmids and 1 mg of pUC-SVNeo were linearized and cotransfected into K562 cells by electroporation (250 V, 950 mF), followed by G418 selection (1 mg ml À1 ). Once drug-resistant populations were prepared, the CAT activity was analyzed as previously described. 43 To analyze the level of CAT mRNA, total RNAs were prepared from respective G418-resistant cells using Trizol reagent (Invitrogen, Carlsbad, CA, USA). cDNAs were synthesized from 1 mg of each RNA sample by using an oligo(dT) primer (Invitrogen) and AMV-RT enzyme (Roche). Real-time quantitative PCR was performed according to the ABI 7300 system's protocol (Applied Biosystems, Foster City, CA, USA), using the following primers: CAT forward, 5¢-CGCAAGATGTGGCGTGTTAC-3¢, CAT reverse, 5¢-CAGCGGCATCAGCACCTT-3¢, b-actin forward, 5¢-CAGCGGAA CCGCTCATTGCCAATGG-3¢, b-actin reverse, 5¢-TCACCCACACTGTGC CCATCTACGA-3¢.
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